Trial Profile
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Abiraterone; Cabazitaxel; Docetaxel; Enzalutamide; Lutetium-177 PSMA therapy; Sipuleucel-T
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REASSURE
- Sponsors Bayer
- 19 Feb 2024 Planned primary completion date changed from 23 Nov 2024 to 2 Aug 2024.
- 27 Jan 2024 Results of safety outcomes in patients with mCRPC treated with Ra-223 following external beam radiation therapy (EBRT) in the US,presented at the 2024 Genitourinary Cancers Symposium
- 17 Jan 2024 According to a Bayer media release, company will also present new data from this REASSURE observational study evaluating the safety outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with XOFIGO (radium Ra 223 dichloride) following EBRT in the U.S. subset of patients enrolled at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.